

STIC-ILL

From: Huynh, Phuong N.
Sent: Thursday, June 20, 2002 6:57 PM
To: STIC-ILL
Subject: RE: 09/674,857

Please deliver the following:

J Immunol 2002 May 1;168(9):4462-71

Immunology 2002 Jan;105(1):9-19

Clinical immunology 98(2): 164-74; 2001

J Exp Med 1991 Jun 1;173(6):1483-91

Eur J Immunology 18(11): 1739-43; 1988

Thanks,
Neon
Art unit 1644
Mail 9E12
Tel 308-4844

NPL

QR 180.36

Alefacept, an Immunomodulatory Recombinant LFA-3/IgG1 Fusion Protein, Induces CD16 Signaling and CD2/CD16-Dependent Apoptosis of CD2⁺ Cells¹

Antonio J. da Silva,² Margot Brickelmaier, Gerard R. Majeau, Zhifang Li, Lihe Su, Yen-Ming Hsu, and Paula S. Hochman

Alefacept, an immunomodulatory recombinant fusion protein composed of the first extracellular domain of LFA-3 fused to the human IgG1 hinge, C_H2, and C_H3 domains, has recently been shown in phase II and III clinical trials to safely reduce disease expression in patients with chronic plaque psoriasis. Alefacept modulates the function of and selectively induces apoptosis of CD2⁺ human memory-effector T cells in vivo. We have sought to gain further understanding of the mechanisms of action that influence the biological activity of alefacept and may contribute to its efficacy and patient responsiveness. Specifically evaluated is the ability of alefacept to activate intracellular signals mediated via CD2 and/or FcγRIII (CD16). Experimentation using isoforms of alefacept engineered to have amino acid substitutions in the IgG1 C_H2 domain that impact FcγR binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2. Experimentation using human CD2-transgenic mice and isoforms of alefacept confirmed the requirement for FcγR binding for detection of the pharmacological effects of alefacept in vivo. Thus alefacept acts as an effector molecule, mediating cognate interactions to activate FcγR⁺ cells (e.g., NK cells) to induce apoptosis of sensitive CD2⁺ target cells. *The Journal of Immunology*, 2002, 168: 4462–4471.

Despite progress in the clinical development of mAbs and IgG fusion proteins as therapeutics, the mechanism(s) contributing to their efficacy and patient responsiveness is still largely undefined (reviewed in Refs. 1 and 2). Although initial evaluations of Ig-based therapeutics focused on antagonism or agonism of cellular processes mediated upon ligation of the targeted ligand, it is now apparent that the Fc regions of Ig-based agents also may contribute to their biological activity (3, 4). Thus, both regions may be engineered to enhance the therapeutics' pharmacokinetics and pharmacodynamics to maximize efficacy. More specifically, chemical and genetic modifications can be made to alter the specificity/affinity of binding: 1) to ligand on target cells (5) and 2) of the Ig Fc domains to complement, FcRn, and FcR (6–9). The three classes of differentially expressed IgG Fc receptors are functionally of two types: the multimeric activation receptors FcγRI (CD64) and FcγRIII (CD16) comprised of both an Fc-binding and a signaling subunit (the immunoreceptor tyrosine-based activation motif), and a inhibitory receptor, monomeric FcγRII (CD32), containing an immunoreceptor tyrosine-based inhibitory motif (6). In this context rational design of the IgG Fc domains of therapeutics can thus select for or against the recruit-

ment of indirect host effects, such as the release of inflammatory cytokines, immune regulation, Ag presentation, target cell death (e.g., complement-dependent cytotoxicity (necrosis) or Ab-dependent cell-mediated cytotoxicity (apoptosis)), endocytosis, and phagocytosis (4, 6). Moreover, engineering of IgG-based therapeutics may address patient-specific factors, such as ligand or Fc receptor polymorphisms, which potentially may differ in control and diseased populations and are likely to be reflected in therapeutic efficacy in vivo. This has been suggested for the therapeutic mAbs Herceptin and Rituxan (both from Genentech, South San Francisco, CA), specific for the signaling receptors *c-erbB-2* and CD20, respectively (10–12). Initially it was postulated that the therapeutic activities of these mAbs might derive solely from the agonistic or antagonistic functions mediated upon binding of their complementarity-determining regions to their molecular target on cells. More recent data from experimental models suggest that the molecular mechanism(s) underlying the biologic activities of Herceptin and Rituxan (4) and alefacept, the CD2 receptor-specific therapeutic LFA-3/IgG1 fusion protein (13, 14), may also reside with IgG Fc-recruited host effector functions, including the activation of apoptosis and Ig-dependent cellular cytotoxicity (e.g., ADCC). As such, clinical and experimental exploration of the relative benefits of human Fcγ isoforms of such therapeutic constructs that differ with regard to their ability to mediate effector functions are prescribed.

Alefacept (human LFA-3/IgG1 fusion protein), previously referred to as LFA3TIP, is an immunomodulatory recombinant fusion protein composed of the first extracellular domain of LFA-3 fused to the human IgG1 hinge, C_H2, and C_H3 domains (13). LFA-3 (CD58) is the primary physiologic ligand for human CD2 and is expressed on many cell types, including APCs (reviewed in Ref. 15). In contrast, human CD2 has a more restricted distribution.

Biogen, Inc., Cambridge, MA 02142

Received for publication December 17, 2001. Accepted for publication February 27, 2002.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Alefacept (human LFA-3/IgG1 fusion protein) is currently being developed under the brand name AMEVIVE (Biogen, Cambridge, MA).

² Address correspondence and reprint requests to Dr. Antonio J. da Silva, Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142. E-mail address: antonio_dasilva@biogen.com

being detected primarily on T cells and NK cells (reviewed in Ref. 16), with elevated expression noted on activated or memory-effector CD45RO⁺ T cells (17–19). Engagement of CD2 on responder T or NK cells by LFA-3 on accessory cells costimulates immune responses potentially by improving the avidity of cellular interactions or by mediating activating signals in the responder cells (15, 16). Indeed, anti-CD2 mAbs and soluble forms of LFA-3, including LFA-3/IgG1 fusion proteins, have been shown to costimulate T cell activation and proliferation under certain experimental conditions (20, 21). Additionally, however, both alefacept and Abs specific for human CD2 and human LFA-3 have been shown to inhibit T cell activities in vitro and in vivo (13, 14, 22). Recently, alefacept as a monotherapy has been shown in phase II and III clinical trials to reduce disease expression safely in patients with chronic plaque psoriasis (23) (M. Lebwohl, E. Christophers, R. Langley, J.-P. Ortonne, J. Roberts, C. E. M. Griffiths, and the Alefacept Clinical Study Group, manuscript in preparation and G. Krueger, K. Papp, D. Stough, K. Loven, W. Gulliver, C. Ellis, and the Alefacept Clinical Study Group, manuscript in preparation), consistent with reports that T cells are central to the underlying pathogenesis (24, 25). The clinical trial data show that alefacept targets the memory-effector CD45RO⁺ T cells thought to be responsible for disease activity and induces sustained remissions that are maintained even after therapy is withdrawn. Herein, we report investigations evaluating the biological activities of alefacept by employing wild-type and Fc γ isoforms of alefacept in vitro and in vivo to gain understanding of mechanisms that may contribute to the efficacy of and patient responsiveness to alefacept.

Materials and Methods

Cells

Human PBL were separated from freshly drawn blood using Ficoll-Hypaque (ICN Biomedicals, Aurora, OH) gradient centrifugation, as previously described (14). NK cells were then enriched using anti-CD3-coated magnetic beads and a Miltenyi Biotec MACS column, following the manufacturer's instructions (Miltenyi, Auburn, CA). Up to 1×10^9 PBL were bound to the anti-CD3-coated beads and passed over the MACS column. The CD3⁺ cells were collected, washed, and run over the same column. The yield of CD3⁺ cells was approximately 10%. This population was cultured (50,000–100,000 cells/well) with irradiated feeders (200,000/well human PBLs exposed to 3000 rad) in wells of 96-well, round-bottom plates using Iscove's (Life Technologies, Grand Island, NY), 10% AB-matched human serum (BioWhittaker, Walkersville, MD), 1% glutamine, 1% penicillin/streptomycin (Life Technologies), 5.0 μ g/ml PHA (Difco, Detroit, MI), and 100 U/ml rIL-2 (R&D Systems, Minneapolis, MN). Cells were fed on day 2 and restimulated on day 5 with irradiated feeders using medium without PHA, but with 5% (v/v) purified IL-2 (Hemagen, Columbia, MD). Cells were fed every other day until growth in the well was obvious, at which time cells were split 1:1. NK cell culture can continue up to approximately 30 days after the initiation of culture. Phenotypic analyses of in vitro-cultured NK cells demonstrated that the cells were >90% NK cells (CD2⁺, CD56⁺, CD16 (Fc γ RIII)⁺, CD3⁺; data not shown) at approximately 2–3 wk after the initiation of culture. T cells were also prepared by culturing Ficoll-Hypaque gradient-separated human PBL (2×10^6 /ml) with OKT3 (10 ng/ml) in complete RPMI (Life Technologies) for 3 days. Cells were then split 1:1 using complete RPMI supplemented with recombinant human IL-2 (5 ng/ml). After 2 additional days of culture, cells were used for cell death studies. Cultures were maintained in the IL-2-supplemented medium for up to 21 days.

Cell lines

The U937 monocytic cell line expressing CD64 (Fc γ RI) and CD32 (Fc γ RII) and the CD2⁺ CHO transfectants have been described previously (14). The CD2⁺CD3⁺CD16⁺ Jurkat tumor T cell line was originally obtained from Dr. Steve Burakoff (Dana-Farber Cancer Institute, Boston, MA). CD2⁺CD3⁺CD16⁺ (Fc γ RIII⁺) Jurkat cells, obtained from Dr. Paul Anderson (Dana-Farber Cancer Institute, Boston, MA), have been described previously (14, 26). Subsequently, variants of Jurkat cells were generated by transfecting the CD2⁺CD3⁺CD16⁺ Jurkat E6-1 clone (ATCC TIB-152; American Type Culture Collection, Manassas, VA) with CD16 cDNA inserted into the pEF-BOS-derived vector (27). The CD16

cDNA was generated by RT-PCR from RNA extracted from the CD16⁺ Jurkat cells (26). Cotransfections were conducted by electroporation of the CD16 construct with a vector carrying the neomycin resistance gene (pGX-N28) for positive selection. Stable transfectants were isolated and expanded by selection with geneticin (G418 sulfate). The cells were then sorted by FACS to isolate populations observed to be phenotypically CD2⁺CD3⁺CD16⁺ or CD2⁺CD3⁺CD16⁺. The expressed recombinant CD16 is expected to form a heterodimeric receptor complex with the TCR ζ -chain to allow for CD16-generated signaling cascades (6, 26). These cells were transiently transfected with a reporter gene construct (NFAT-luciferase; Clontech, Palo Alto, CA) and assayed as described below.

Fusion proteins

Alefacept is composed of the first extracellular domain of LFA-3 fused to the hinge, C_H2 domain, and C_H3 domain of human IgG1. Its construction, expression, and purification have been described previously (13). Constructs encoding fusion proteins identical with alefacept, but with mutations encoding amino acid substitutions at alefacept positions 106, 107, and 109, which correspond to amino acid positions 234, 235, and 237 (according to European Union numbering) of the human IgG1 C_H2 domain, or only at alefacept position 107 (amino acid 235 of human IgG1) were also prepared. These constructs, designated CA139 and L107E, respectively, were expressed transiently in CHO-S cells, and the proteins derived were purified on a protein A column (Amersham/Pharmacia, Piscataway, NJ). The concentration was determined as the absorbance at 280 nm divided by the extinction coefficient (1.47). CA139 has the following amino acid substitutions in the alefacept IgG1 C_H2 domain: leucine to alanine at alefacept position 106, leucine to glutamic acid at position 107, and glycine to alanine at position 109. L107E has only the leucine to glutamic acid substitution at alefacept position 107. A lymphotoxin β receptor (LT β R)/IgG1 fusion protein possessing the same human IgG1 Fc hinge, C_H2, and C_H3 regions as alefacept was employed as a control in the studies herein (28).

Antibodies

The human CD2-specific mAbs GD10 and CB6, both murine IgG1, were prepared at Biogen (Cambridge, MA) using standard techniques. Briefly, RBF mice were immunized via the i.p. route simultaneously with CFA and 4×10^6 CHO transfectants expressing human CD2. Mice were boosted five times via the i.p. route at 2- to 3-wk intervals with both 4×10^6 CD2⁺ CHO transfectants and IFA. Three days after the fifth boost, mice with sera exhibiting human CD2-specific Abs received an i.p. injection of CD2⁺ CHO transfectants and were then sacrificed, and their spleen cells were harvested and fused to APRT-P3X.653 myeloma cells. After hybridomas were selected in medium containing adenine-aminopterin-thymidine, hybridoma supernatants were screened for binding to CD2⁺ Jurkat cells. Selected hybridoma subclones were grown in BALB/c mice as ascetic tumors, and Abs were purified by protein A-Sepharose chromatography following standard procedures. The agonist human CD3-specific mAb OKT3 is a murine IgG2a (ATCC). The agonist anti-CD16 mAb (murine IgG1, clone 3G8) was purchased from BD PharMingen (San Diego, CA) and Medarex (Annandale, NJ). The Fas (CD95)-specific murine IgM mAb CH11 was purchased from Kamiya Biomedical (Seattle, WA). The blocking human CD2 specific mAb TS2/18 was gift from Dr. T. Springer (Harvard Medical School, Boston, MA). A murine IgG1 and the control MOPC21, a murine IgG1, were purchased from Sigma (St. Louis, MO).

Human CD2⁺ transgenic mice

Male and female 2- to 3-mo-old transgenic mice expressing one copy of the human CD2 gene received one i.v. injection of a 100- μ l volume of fusion protein. Mice were bled on the day after injection. PBL were stained using FITC-conjugated Abs specific for human CD2 (Leu 5b; BD Biosciences, San Diego, CA) and murine CD3 (mAb 145-2C11, purchased from PharMingen), which are T cell markers, and with a FITC-conjugated Ab specific for murine IgM (Jackson ImmunoResearch Laboratory, West Grove, PA), which is a marker for B cells. Cell staining was evaluated by flow cytometry.

Flow cytometry

Binding assays were performed as described previously (19). In vitro IL-2-expanded NK cells (3×10^5) were incubated at room temperature for 30 min with various concentrations of alefacept as indicated in the figure or with commercially available CD-specific mAb reagents to which a fluorescent tag was directly conjugated. To detect alefacept binding, cells were then washed twice with PBS and 0.5% BSA and incubated with a 1/200

dilution of PE-conjugated goat anti-human IgG (Jackson ImmunoResearch Laboratories) for 30 min at room temperature. Cells were then washed twice, fixed with 1% paraformaldehyde, and analyzed by flow cytometry using a FACSCalibur flow cytometer (BD Biosciences). Ten thousand events were monitored. Reagents specific for human CD2, CD16, CD3, CD25, CD69, and Fas (CD95) used for flow cytometry were purchased from PharMingen. To detect NK cells, PBL were stained with FITC-conjugated mouse anti-human CD16 and CyChrome-conjugated mouse anti-human CD56 (BD PharMingen). Data are expressed as the median fluorescent channel intensity.

ELISA for granzyme B

An ELISA for detection of granzyme B in supernatants derived from stimulated NK cells was based on that previously reported (29). Briefly, purified mAb GB11 (Research Diagnostics, Flanders, NJ) specific for granzyme B was coated (50 mM sodium carbonate/bicarbonate coating buffer, pH 9.6, 16 h at 4°C) on the wells of Nunc Polysorp immunoplate (Copenhagen, Denmark). Following washing (PBS/0.05% Tween 20 and blocking (PBS/2% (w/v) milk, 1 h at room temperature), purified granzyme B (Calbiochem, La Jolla, CA) as a standard and samples that had been treated with hyaluronidase (Sigma; 40 µg/ml for 30 min at room temperature) and diluted in PBS were added (100 µl/well), and plates were incubated for 2 h at room temperature. Following washing, the detecting granzyme B-specific Ab, biotinylated GB10 mAb (0.5 µg/ml in PBS/1% normal mouse serum) was added, and plates were incubated for 1 h. Following another wash, the plate was incubated for 30 min with HRP-streptavidin (Jackson ImmunoResearch; 1/20,000 diluted in PBS/1% normal mouse serum). The plate was washed and developed in 100 µl of 0.42 mM 3,3',5,5'-tetramethylbenzidine in 0.1 M sodium acetate-citric acid, pH 4.9, and 0.003% (v/v) H₂O₂. The reaction was stopped with an equal volume of 2 N H₂SO₄ to the wells, and the plate was read on a Microbeta Jet plate reader (Molecular Devices, Menlo Park, CA) at 450 nm.

Alefacept-mediated bridging assay

Bridging assays were performed as described previously (14). CHO cells transfected with human CD2 were grown to confluence in wells of flat-bottom, 96-well plates. Wells were washed twice, 50 µl of varying concentrations of fusion protein were added, and plates were incubated for 30 min at 37°C. One hundred thousand U937 cells (expressing CD64 and CD32) or 10⁵ CD16⁺ Jurkat cells labeled with 2-7-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (Molecular Probes, Eugene, OR) according to the manufacturer's directions were then added in 50 µl to wells. Plates were incubated for 30 min at 37°C. Wells were then washed up to four times. Background signal was that of wells with cells but without added fusion protein, incubated and washed as were the experimental groups. Total input signal was defined as the fluorescence signal released from 10⁵ BCECF-AM-labeled cells. The percent binding was determined as the (observed - background)/(total input - background) fluorescence × 100.

T cell proliferation assays

Human PBL (1–2 × 10⁵/well) were suspended in complete medium (RPMI 1640 supplemented with 10% heat-inactivated FBS, 1% HEPES, 1% penicillin (100,000 U/ml), 1% streptomycin (10,000 µg/ml), and 2% glutamine (200 mmol/l)) and cultured in 96-well microtiter plates. PHA or irradiated (10,000 rad) human allogeneic JY tumor B cells serving as APC were added, and plates were incubated at 37°C in 5% CO₂. MLR were incubated for a total of 6 days. PHA-induced proliferation assays were incubated for a total of 3 days. Wells were pulsed with 1 µCi tritiated thymidine ([³H]TdR; Amersham) for 18 h before harvesting cells onto glass-fiber filters using a MASH harvester (Tomtec, Orange, CT). Radioactivity incorporated was measured using a liquid scintillation counter (Wallac, Gaithersburg, MD).

Cell death assays

Cell death was measured by flow cytometry or in standard cell-mediated cytotoxicity assays. Death of in vitro IL-2 expanded NK or T cells or of Jurkat cells, which had been stimulated as described in Results, was detected by staining with FITC-annexin followed by flow cytometric analyses. Cell death was also measured in nonradioactive standard cell-mediated cytotoxicity assays using a commercially available kit (CytoTox96; Promega, Madison, WI). Briefly, 30,000 NK cells in 0.1 ml were added to wells of round-bottom, 96-well microtiter plates. Fusion proteins were added to wells at the concentrations shown in the figures to make a total volume of 0.2 ml/well. The microtiter plates were incubated (37°C, 5% CO₂) for 4 h, and then 0.05 ml supernatant was removed for measurement

of released lactic dehydrogenase (LDH)³ according to kit instructions, and absorbance was read at 490 nm in a Molecular Devices Spectramax Plus plate reader. Spontaneous release (SR) is LDH released from the cells in the presence of medium alone, and maximum release was that released from the cells incubated in the presence of 9% Triton X-100. Percent lysis was calculated as ((experimental - SR)/(maximum release - SR)) × 100. Concanamycin A (Sequoia, St. Louis, MO), an inhibitor of vacuolar type H⁺-ATPase thus perforin-based cytotoxic activity (30), was employed at a 50-nM concentration. Granzyme B-mediated cell death is referred to herein as apoptosis (contrasting with necrosis mediated by the complement membrane attack complex), as it is known to activate the caspase cascade in target cells to cause cell death.

p42/44^{MAPK} (extracellular signal-regulated kinase (ERK)) activation assay

Jurkat cells (2 × 10⁶ cells in 1 ml RPMI medium with 2% FBS) were treated in vitro for 12 min at 37°C with either fusion proteins or mAbs as indicated in the figure legends. Following stimulation, cells were sedimented by brief centrifugation, and the pellet was resuspended in 100 µl of a hypotonic solution (10 mM Tris and 1 mM EDTA buffer). After addition of an equal volume of gel loading buffer, cell extracts were separated by 12.5% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA), and the samples were subjected to immunoblotting with phospho-specific Abs to p42/44^{MAPK} specific for activated kinase. Blots were developed using the ECL system and were visualized by exposure to x-ray film. Autoradiographs were scanned using a densitometer.

Luciferase reporter assays

Cells (2 × 10⁷ cells in 400 µl) were transfected with 80 µg pNFAT-luciferase reporter gene construct (Stratagene, La Jolla, CA) and then diluted into 20 ml RPMI medium supplemented with 10% FBS and incubated (5% CO₂, 37°C) overnight. To measure the induction of luciferase expression, cells were treated with either a combination of PMA (Calbiochem, La Jolla, CA) and ionomycin (Calbiochem) at concentrations of 0.1 and 5 µg/ml, respectively, or with mAbs and fusion proteins in wells of a 96-well, round-bottom well plate. Following 4–6 h of incubation (5% CO₂, 37°C), the plate was centrifuged (800 × g for 5 min), the cells were lysed in 100 µl of 1× reporter lysis buffer (Promega, Madison, WI) for 10 min while being shaken at room temperature. The cell lysates (40 µl) were transferred into wells of a white isoplate, 75 µl luciferase substrate was added to each well, and after 1 s the luminescence was counted for 1 s using a Microbeta jet reader (Wallac, Gaithersburg, MD). The data are expressed as corrected light units per second (CLPS). The signal was normalized by dividing the CLPS values for each experimental well by the average CLPS value of the OKT3-treated sample and then multiplied by 100. Thus, the signals are represented as a percentage of the CD3-stimulated signal.

Ribonuclease protection assays (RPAs)

IL-2-expanded NK cells were incubated for 48 h in fresh medium containing 5% IL-2 (purified), after which they were incubated with the various mAbs and fusion proteins in the same conditioned medium. Thirty × 10⁶ cells were used per experimental condition. After 4 h of incubation at 37°C, cells were harvested, and RNA was extracted (Qiagen, Valencia, CA). To perform the RPAs, 10 µg of each RNA sample was then hybridized overnight separately with three [³²P]dCTP (Amersham)-labeled probe sets: huCK-1 (cytokines), and APO-3 and APO-4 (apoptotic genes) as indicated by the manufacturer (BD PharMingen). The RNA/probe hybrids were then treated with RNase A to digest unprotected RNA. After proteinase K treatment, the RNase digests were phenol extracted once, precipitated with ethanol, and separated by QuickPoint acrylamide gel electrophoresis (Novex, San Diego, CA). Labeled probes were visualized by autoradiography, and the intensity of the signal was measured with a Storm 860 PhosphorImager scanner (Molecular Dynamics, Sunnyvale, CA). Hybridization signals for the individual mRNA species were then normalized against the mean value obtained for the GAPDH/L23 signals (×100) within each experimental sample. Hence, the detected expression levels for the genes of interest are expressed relative to the expression levels observed for two housekeeping genes. Individual mRNA species were identified against labeled standards following the manufacturer's procedures.

³ Abbreviations used in this paper: LDH, lactic dehydrogenase; CLPS, corrected light units per second; ERK, extracellular signal-regulated kinase; LTβR, lymphotoxin β receptor; RPA, RNase protection assay; SR, spontaneous release.

Results

Alefacept engages CD2 and FcγR to mediate cognate cell interactions required to inhibit T cell proliferation in vitro

To investigate the role of the IgG1 Fc portion and cell-expressed FcγR (particularly FcγRIII, CD16) in the functional activity of alefacept, two isoforms expressing mutations in the human IgG1 C_H2 domain of the fusion protein were generated. These isoforms, designated L107E and CA139, were mutated, respectively, at IgG1 H chain aa position 235 only or at 234, 235, and 237 (employing the European Union nomenclature). These amino acid substitutions are expected to abrogate binding to FcγR (31, 32). Initial experiments compared the binding of alefacept and CA139 to freshly drawn human peripheral blood T cells or to in vitro IL-2-expanded human NK cells that express CD2 and CD16 (Fig. 1, A and B, respectively). Bound fusion proteins were detected using flow cytometry. The concentration range for saturation binding was not addressed in these experiments, as equilibrium conditions were not established. The shapes of the binding profiles of alefacept and CA139 to T cells (detected in Fig. 1A as CD2⁺CD16⁺CD56⁺ peripheral blood cells) were similar in that binding is detected primarily at high (>100 μg/ml) and less so at lower (1–100 μg/ml) alefacept concentrations. In contrast, alefacept binds to the in vitro cultured NK cells (which are CD2⁺CD16⁺, Fig. 1B) at high as well as lower concentrations. CA139 (which binds CD2, but not CD16; see below) appears to bind better at higher and less well at the lower fusion protein concentrations. The binding of both fusion proteins (at all concentra-

tions tested) is inhibited by 15 μg/ml of the CD2-specific mAb TS2/18, but not by isotype control murine IgG1 MOPC21 (Fig. 1B). These data are consistent with published results (19) showing that high avidity binding at the lower alefacept concentrations reflects binding to both CD2 and CD16, and low affinity binding at higher alefacept concentrations reflects LFA-3 binding to CD2 only.

Next we tested the ability of alefacept, CA139, or L107E to mediate intercellular bridging of plate-adherent CD2⁺ CHO transfectants to fluorescently labeled CD64⁺ CD32⁺ (FcγRI and FcγRII, respectively) U937 cells or CD16⁺ (FcγRIII)-transfected Jurkat cells (14). As shown in Fig. 1C, alefacept mediates intercellular bridging, whereas both CA139 and L107E failed to bridge in assays employing U937 cells. In contrast, both alefacept and L107E mediated intercellular bridging of CD16⁺ Jurkat cells to CD2⁺ CHO transfectants, and CA139 failed to bridge CD16⁺ Jurkat cells to CD2⁺ CHO transfectants (Fig. 1D). Thus, the mutations in CA139 abrogated bridging of CD2⁺ cells to either CD64⁺CD32⁺ cells or CD16⁺ cells, whereas the mutation in L107E abrogated bridging of CD2⁺ cells only to CD64⁺CD32⁺ cells, leaving bridging to CD16⁺ cells intact.

The effects of alefacept, L107E, and CA139 on human T cell proliferation in vitro were evaluated. Fig. 1, E and F, shows, respectively, the effects of addition of various concentrations of the fusion proteins to cultures of human PBL induced to proliferate in response to PHA and in allogeneic MLR employing as stimulators the JY human B cell line. Both alefacept and L107E inhibited T




FIGURE 1. Alefacept binding mediates cognate interactions between CD2⁺ and FcR⁺ cells to inhibit T cell proliferation. **A**, Binding of alefacept or its isoform CA139 to T cells (CD56⁺CD16⁺ peripheral blood cells) was detected by immunofluorescent staining with a PE-conjugated anti-human IgG (HuIgG). Median fluorescent channel intensity (MFCI) values are plotted vs ligand concentration. **B**, In vitro expanded NK cells were preincubated with the CD2-specific mAb TS2/18 (15 μg/ml) or isotype control MOPC21 (66 μg/ml), then incubated for an additional 30 min at room temperature with alefacept or CA139 (at the final concentrations shown on the x-axis) and washed twice, and bound alefacept or CA139 was detected. **C** and **D**, Monolayers of CD2-transfected CHO cells were incubated with the indicated concentrations of alefacept, CA139, or L107E. BCECF-AM-labeled CD32⁺, CD64⁺ U937 (C), or CD16⁺-transfected Jurkat cells (D) were then added, and incubation was continued. Following washing, plates were read at 485/530 nm to determine the percentage of cell bridging. **E** and **F**, Human PBL were cultured with PHA (E) in the presence of the reagents designated on the x-axis at the concentrations shown in the legend for a total of 3 days, or were coincubated (F) with irradiated JY B tumor cells serving as APC in the presence of the reagents on the x-axis for a total of 6 days. Wells were pulsed with 1 μCi [³H]Tdr for 18 h before harvesting cells; the radioactivity incorporated was measured using a liquid scintillation counter.

cell proliferation comparably in such assays. In contrast, CA139 had little effect. This pattern confirms a role for CD16 binding as well as CD2 binding in alefacept inhibition of T cell proliferation (14). As T and B cells do not express CD16, it is likely that the required CD16⁺ cells are NK cells or macrophages in the responder PBL preparation.

Alefacept's effects on peripheral T cells in human CD2 transgenic mice is dependent on human CD2 and FcγR binding in vivo

With regard to alefacept's effects on T cells in vivo, it has previously been shown that a single injection of $\geq 50 \mu\text{g}$ ($\sim 2.5 \text{ mg/kg}$) alefacept into human CD2 transgenic mice diminished human CD2⁺ murine T cells in the blood and secondary lymphoid tissues by a mechanism that does not require complement but is dependent on the expression of the IgG1 C_H2 domain by the fusion protein (14). Human CD2 transgenic mice were used, as the endogenous murine CD2 does not bind human LFA-3 expressed in alefacept (14); in fact, the receptor for murine CD2 is murine CD48 (33), and an LFA-3(CD58) equivalent has not been identified in mice. The data from a representative experiment (Table I) show that administration of 50 μg alefacept or L107E eliminated peripheral human CD2⁺ T cells from human CD2⁺ transgenic mice. The percentage of peripheral blood (human CD2⁺, murine CD3⁺) T cells observed on days 2 and 3 postdosing was 0 or 1%, compared with approximately 35% human CD2⁺ and murine CD3⁺ T cells in untreated mice. The percentage of PBL that were IgM⁺ B cells was $>85\%$ in the alefacept- and L107E-treated mice compared with approximately 50% in untreated mice, showing a corresponding increase in the percentage of B cells as the T cell counts decreased. In contrast, administration of CA139 to human CD2 transgenic mice had no effect on peripheral T cell counts. ELISA analyses of plasma samples taken from the mice at the time of the flow cytometric analyses showed approximately equivalent fusion protein concentrations (data not shown). Thus, CA139, which binds to CD2, but not to human, CD64, CD32, and CD16, fails to reduce, whereas the L107E mutant, which binds human CD2 and human CD16, is able to reduce peripheral T cell counts in human CD2 transgenic mice comparably to alefacept. Thus, this in vivo effect of alefacept on peripheral T cells requires that the fusion protein bind to cells that express the murine homologue of human

FcγRIII, but not FcγRI or FcγRII, and cells that express human CD2. As published data indicate that anti-asialo GM1 pretreatment of human CD2 transgenic mice to remove NK cells did not abrogate alefacept's activity (14), other FcγR⁺ murine cells, e.g., macrophages, may also mediate alefacept's effect on T cells in these mice.

Alefacept and L107E, but not CA139, induce apoptosis of in vitro IL-2-expanded NK cells and CD16-transfected Jurkat cells

As the studies reported above and previously show a role for LFA-3 and human IgG1 Fc binding, respectively, to CD2 expressed on T (and NK) cells and the CD16 expressed by NK cells and potentially macrophages in alefacept's effects on T cell proliferation in vitro and on peripheral T cell counts in vivo, it was of interest to evaluate the effect of the fusion protein directly on CD16-expressing cells. For this purpose we employed a homogeneous population of primary cells that express CD16, which are capable of lytic function. Specifically, the effect of alefacept and its mutant isoforms on in vitro propagated CD16⁺CD2⁺ NK cells was examined. Initially, alefacept was tested for its ability to induce apoptosis of human NK or T cells. Relatively homogeneous preparations of in vitro IL-2-expanded NK or T cells were incubated with various concentrations of alefacept, CA139, anti-CD16 mAb, or their isotype controls, human LTβR/IgG1 Fc-fusion protein (LTβR/IgG1), and MOPC21. Following incubation, the cells were collected and stained with FITC-conjugated annexin V. An increase in the percentage of cells binding annexin V represents an increase in apoptotic cells, as annexin V binds phosphatidyl serine, which is known to flip from the inner to the outer membrane of the cytoplasmic membrane when cells undergo apoptosis. As shown in Table II, incubation of NK cells with alefacept or the CD16-specific mAb, but not CA139, LTβR/IgG1, or MOPC21, resulted in a substantial increase in the percentage of NK cells that bind annexin

Table I. Effects of CA139 and alefacept in transgenic mice expressing human CD2^a

Treatment of CD2 ⁺ Transgenic Mice	μg/Mouse	% of Cells Expressing		
		Human CD2	Murine CD3	Murine IgM
Untreated	NA	32	32	59
		36	39	53
Alefacept	50	0	1	86
	50	0	1	92
	50	0	1	89
	50	0	1	89
L107E	50	0	1	85
	50	0	1	88
	50	0	1	87
	50	0	1	89
CA139	50	30	31	65
	50	36	38	48
	50	32	35	59
	50	32	34	58

^a Fusion proteins were administered in a volume of 0.1 ml by the i.v. route. Surface staining was determined by flow cytometry 1 day posttreatment.

Table II. Alefacept-induced release of granzyme B and apoptosis of in vitro IL-2-expanded NK cells requires coengagement of CD2 and FcγR^a

Treatment of Cells	Concentration (μg/ml)	Apoptosis Measured as % Cells Binding Annexin V	Granzyme B (ng/ml (SD))
None	NA	21	24.6 (3.0)
Ethanol	NA	89	37.0 (9.8)
Alefacept	10	62	47.1 (9.7)
	1	56	36.1 (5.4)
	0.1	34	24.4 (1.7)
	0.01	25	18.6 (0.4)
	0.001	25	18.0 (0.1)
CA139	10	24	15.5 (1.4)
	1	31	Not done
	0.1	25	16.9 (0.3)
	0.01	24	17.8 (0.1)
	0.001	25	16.3 (1.0)
LTβR/IgG1	10	33	26.6 (2.3)
	1	31	23.2 (0.9)
	0.1	28	18.0 (0.3)
	0.01	27	22.7 (0.4)
	0.001	27	19.2 (0.4)
Anti-CD16 mAb	5	62	38.3 (11.5)
	0.5	57	59.3 (18.0)
	0.05	48	33.2 (3.3)
	0.005	30	21.5 (0.8)
MOPC21	5	23	19.8 (0.8)

^a NK cells (day 22) were cultured for 24 h with the reagents at the concentrations indicated. Cells were collected and stained with fluoresceinated annexin V and analyzed by flow cytometry. Supernatants from the same cultures were assessed by ELISA for the presence of granzyme B. NA, Not applicable.

V. In a parallel experiment using the homogeneous preparations of IL-2-expanded T cells (that lack CD16 expression on the surface), the T cell population was induced to undergo apoptosis by camptothecin and Fas- or CD2-specific mAbs, but not by either alefacept or CA139 (data not shown). This indicates that alefacept is able to induce apoptosis of *in vitro* IL-2-expanded NK cells, but not that of *in vitro* IL-2-expanded T cells. As the CD16-specific mAb, but not the control LT β R/IgG1 fusion protein or CA139, also induced NK cell apoptosis, the data indicate that CD16 binding by mAb alone is sufficient to mediate such activity, but that alefacept must bind both CD2 and CD16 to mediate its effect. Similarly, but less impressively, in studies employing Jurkat cells, CD2⁺CD2⁺CD16⁺ Jurkat transfectants incubated with alefacept, but not CA139, were induced to undergo apoptosis (Table III). In contrast, Jurkat cells expressing CD2, but not CD16, were not induced by alefacept to undergo apoptosis (Table III).

The molecular mechanisms contributing to alefacept-induced apoptosis of sensitive CD2⁺ cells were evaluated. First, the ability of alefacept to induce NK cells to secrete granzyme B was assessed. The results shown in Table II demonstrate that the addition of various concentrations of alefacept or the CD16-specific mAb, but not CA139 or LT β R/IgG1, to cultures of NK cells induces the secretion of granzyme B. To evaluate whether this may contribute to alefacept-stimulated NK cell apoptosis, concanamycin A was used in 4-h cytotoxicity assays. Concanamycin A is an inhibitor of vacuolar type H⁺-ATPase and inhibits perforin-based cytotoxic activity primarily due to accelerated degradation of perforin by an increase in the pH of lytic granules. In a representative experiment shown in Fig. 2A, IL-2-expanded NK cells were incubated with alefacept or the control protein LT β R/IgG1 for 4 h in the presence or the absence of concanamycin A, and cytotoxicity was measured as an increase in the release of LDH by the NK cells. The data show that concanamycin A almost completely inhibited alefacept-induced NK cell death detected in 4-h cytotoxicity assays. Thus, in these IL-2-expanded NK cells, alefacept appears to induce apoptosis by a mechanism that is mediated primarily by granzyme B. By contrast concanamycin A only partially reduced NK cell lysis of K562 target cells (data not shown), consistent with published data suggesting that NK cell-mediated lysis of K562 cells reflects the activity of both the perforin/granzyme B and the Fas ligand/Fas death receptor pathways (34). Attempts to investigate the induction of caspase activity in response to alefacept or control fusion proteins or mAbs were difficult due to high levels of endogenous




FIGURE 2. Alefacept induces activation and concanamycin A-inhibitable cytotoxicity of NK cells. **A.** *In vitro* IL-2-expanded NK cells (day 29) were preincubated (or not) for 2 h with 50 nM CMA. These cells were then further incubated with the indicated concentration of fusion proteins for 4 h. Supernatants were removed to allow the measurements of released LDH as a means of quantitating cell lysis. **B.** *In vitro* expanded NK cells (day 21) were incubated for 20 h with medium alone or with 10 μ g/ml alefacept, CA139, LT β R/IgG1, anti-CD2 mAbs (10 μ g/ml each), or anti-CD16 mAb (5 μ g/ml). Cells were washed and then stained with PE-conjugated anti-human CD25 (upper panel) or anti-human Fas (CD95) (lower panel). Cells stained with anti-human Fas were washed and subsequently stained with PE-conjugated goat anti-mouse IgG. Cells were washed again, and the immunofluorescent staining was detected. MFCI, Median fluorescent channel intensity.

caspase activity observed in these *in vitro* IL-2-expanded NK cells (data not shown).

*Alefacept induces activation of and intracellular signaling in *in vitro* IL-2-expanded NK cells that is dependent on CD2 and CD16 binding.*

We next considered that alefacept-mediated apoptosis of NK cells (Fig. 2) may reflect activation-induced intracellular processes similar to the apoptosis of IL-2-activated NK cells stimulated by anti-CD16 mAb (35) or anti-CD2 mAbs (36, 37). Thus, we investigated whether alefacept has agonistic properties. NK cells were incubated with 10 μ g/ml alefacept or control proteins for 20 h in the presence of IL-2 and then analyzed by flow cytometry for the expression of activation markers CD25, and CD95 (Fas). The results show that incubation of NK cells with alefacept, anti-CD2 mAbs, or anti-CD16 mAb, but not CA139 or LT β R/IgG1, resulted in up-regulation of the expression of CD25 (Fig. 2B, upper panel), but not CD95 (Fig. 2B, lower panel), which is already highly expressed by these *in vitro* IL-2 expanded NK cells (Fig. 2B, lower panel). Such an agonistic effect of alefacept on IL-2-expanded human T cells was not noted (data not shown).

Table III. Alefacept induces apoptosis in CD16⁺CD2⁺ Jurkat cells^a

Treatment of Jurkat Cells	Concentration (μ g/ml)	% CD2 ⁺ CD16 ⁺ Jurkat Cells Binding Annexin V	% CD2 ⁺ CD16 ⁺ Jurkat Cells Binding Annexin V
Untreated	NA	19.1	15.3
Ethanol	NA	72.3	55.6
Alefacept	10.0	40	17.1
	1.0	32.0	17.0
	0.1	21.4	17
	0.01	18.3	19.6
CA139	10.0	17	16
	1.0	20.2	14.5
	0.1	18.8	19.3
	0.01	18.6	19.3
LT β R/IgG1	10.0	22.2	15

^a Jurkat cells were cultured for 72 h with the reagents at the concentrations indicated. Cells were collected and stained with fluoresceinated annexin V and analyzed by flow cytometry. NA, Not applicable.

Since both CD2 and CD16 can be engaged to induce intracellular signaling in NK cells (38, 39), the ability of alefacept to induce signaling in *in vitro* IL-2-expanded NK cells was evaluated (Fig. 3A). Incubation of these NK cells with alefacept, but not CA139 or LT β R/IgG1, increased the levels of p42/44^{MAPK} (ERK) phosphorylation approximately 21-fold compared with cells exposed to medium alone (Fig. 3A and data not shown). The anti-CD16 mAb also stimulated increased ERK activation (~18-fold). In contrast, whereas neither the IgG controls (human IgG, MOPC21, and LT β R/IgG1), the anti-CD3 mAb, nor the anti-CD2 mAbs induced activation of ERK in these IL-2-expanded NK cells, even though the anti-CD2 and anti-CD3 mAbs induced high levels of ERK activation in Jurkat cells (see below, Fig. 3B). This indicated that coengagement of CD16 and CD2 by alefacept is required to induce NK cell signaling.

To determine whether alefacept is capable of inducing ERK activation when CD2 or CD16 are expressed on the same or apposing cells, Jurkat transfectants were employed. As shown in Fig. 3B, alefacept induced ERK activation in CD2⁺CD16⁺ Jurkat transfectants or when CD2⁺CD16⁻ and CD2⁻CD16⁺ Jurkat transfectants were cocultured. In contrast, ERK activation was not induced when alefacept was incubated with either the CD2⁺CD16⁻ Jurkats alone or CD2⁻CD16⁺ Jurkat transfectants alone, although these CD3⁻, CD2⁻, or CD16-specific mAbs did induce ERK activation in the Jurkat transfectants expressing the corresponding CD3, CD2, or CD16 cell surface molecule (Fig. 3B). Incubation of the CD2⁺CD3⁺CD16⁺ Jurkat transfectants with an isotype control fusion protein (LT β R/IgG1) or with CA139 failed to induce ERK phosphorylation (data not shown). These results showed again that alefacept must bind to both CD2

and CD16 to induce ERK activation consistent with the data generated with the IL-2-expanded NK cells (Fig. 3A). Importantly, the data demonstrate a functional consequence (ERK activation) of alefacept-mediated cognate interactions between CD2 and CD16 expressed on different cells.

To distinguish whether alefacept induced signaling of Jurkat cells via CD2, CD16, or both, the same stably transfected CD2⁺CD2⁺CD16⁻ and CD2⁻CD2⁺CD16⁺ Jurkat cells were transiently transfected with a pNFAT-luciferase reporter construct. The reporter-expressing Jurkat transfectants were then cultured either individually or with the reciprocal untransfected cells in the presence of alefacept or mAbs specific for either CD2, CD16, or CD3. As shown (Fig. 4), when cultured individually in the presence of alefacept or CA139, neither pNFAT-luciferase Jurkat transfectant was stimulated to activate NFAT. Alefacept (but not CA139) induced NFAT activation when the CD2⁻CD3⁺CD16⁺ Jurkat cells transfected with the reporter construct were cocultured with untransfected CD2⁺CD3⁺CD16⁻ cells (Fig. 4B). In contrast, alefacept did not activate NFAT when pNFAT-luciferase transfected CD2⁺CD3⁺CD16⁻ Jurkat cells were cultured with untransfected CD2⁻CD3⁺CD16⁺ Jurkat cells (Fig. 4A) even though the




FIGURE 3. Alefacept induction of ERK activation requires binding to both CD2 and CD16. *In vitro* IL-2-expanded NK cells that were cultured overnight in IL-2-free medium to bring the cells to a quiescent state (A) or the designated Jurkat transfectants as indicated (B) were incubated for 12 min at 37°C with the proteins or mAbs (5 μ g/ml each) indicated. Cell lysates were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes, and probed with rabbit serum specific for phosphorylated ERK (phospho ERK, top gel) or total ERK (pERK, lower gel). Signals were visualized by chemiluminescence and autoradiography. hulG, Human IgG; Unstim., unstimulated.




FIGURE 4. Alefacept induces activation signals via CD16, but not CD2, in Jurkat cells. A, pNFAT-Luc-transfected CD2⁺CD3⁺CD16⁻ Jurkat cells were cultured alone (solid bar) or cocultured with CD2⁻CD3⁺CD16⁺ untransfected Jurkat cells (squared bar) in the presence of 5 μ g/ml of the mAbs or the fusion proteins designated on the x-axis. B, pNFAT-Luc-transfected CD2⁻CD3⁺CD16⁻ Jurkat cells were cultured alone (solid bar) or cocultured with CD2⁺CD3⁺CD16⁻ untransfected Jurkat cells (squared bar) in the presence of 5 μ g/ml of the mAbs or fusion proteins designated on the x-axis. After a 6-h incubation, luciferase activity was measured, and the signals were normalized by dividing the CLPS values for each experimental well by the average CLPS value of the anti-CD3-treated sample and then multiplying by 100. Thus, the data are represented as a percentage of the CD3-stimulated signal.

CD2-specific mAbs activated NFAT in these reporter cells. Thus, in this Jurkat model system alefacept-induced signaling is primarily mediated by the interaction of its Fc portion with CD16. Although binding of the LFA-3 portion of alefacept to CD2 alone, as in the case of CA139, was not capable of inducing NFAT activity, this CD2/LFA-3 interaction was nevertheless required, since incubation with alefacept, but not a control human IgG1 fusion protein (LT β R/IgG1), induced NFAT activity.

Alefacept activation of IL-2 expanded NK cells generates a gene expression profile similar to that induced with anti-CD16 mAb and distinct from that induced by anti-CD2 mAbs

RPA were performed to evaluate whether alefacept was capable of signaling gene expression in these NK cells and how the expressed patterns compared with those induced by stimulation with mAbs specific for CD2 or CD16. Consistent with the cytolytic functions of NK cells, the IL-2-propagated NK cells constitutively expressed high levels of mRNA for granzyme A, granzyme B, and perforin. These were essentially not up-regulated upon stimulation with alefacept (Table IV), except perhaps marginally for granzyme A mRNA. It is possible that the ability of alefacept to up-regulate these mediators is masked by the propagation of these cells with IL-2, since freshly isolated human NK cells constitutively demonstrate only low expression of granzyme B (and high expression of granzymes A and M, and perforin) (40). Constitutive expression levels of mRNA for other molecules involved in apoptotic pathways, such as granzyme H, granzyme 3, rat ventral prostate (an-

drogen withdrawal apoptosis protein), and various TNF family death receptors and their ligands (Fas, Fas ligand, TNF-related apoptosis-inducing ligand, and TNFRp55), were also moderately high in these IL-2-propagated NK cells (Table IV), with only a suggestion of increases in rat ventral prostate mRNA levels upon stimulation with alefacept. Thus, although spontaneous NK cell killing of tumor cell lines, and Ab-dependent (NK/K) cell-mediated cytotoxicity are reported to be mediated in part by members of the TNF receptor subfamily that express intracellular death domains (41–43), these data do not provide evidence for their role in the biological activity of alefacept. This may reflect the fact that although these ligands and receptors are expressed on NK cells, they may not have a major role in the induction of apoptosis of the NK cells themselves (37, 43–45), consistent with the observation (Fig. 2A) that concanamycin A almost completely inhibited the NK cell apoptosis induced by alefacept.

The cytokine mRNAs evaluated (IL-4, IL-5, IL-13, IL-14, IFN- γ) were expressed at low or undetectable levels and were shown to be robustly up-regulated when the NK cells were stimulated with the agonistic CD2-specific mAb mitogenic pair (Table IV and Fig. 5). In contrast, alefacept and anti-CD16 mAb failed to induce the expression of these genes. An apparent slight increase (3- to 4-fold) in the level of IFN- γ mRNA was observed when the NK cells were stimulated with alefacept, anti-CD16, or LT β R/IgG1, but this effect was slight in comparison with the 23-fold change in the expression levels induced by the anti-CD2 agonist

Table IV. The gene expression profile generated by alefacept in IL-2 in vitro-expanded NK cells is similar to that induced by anti-CD16 but not anti-CD2 mAbs^a

Probe Set	mRNA	Media	MOPC21	Alefacept	CA139	LT β R/IG	Anti-CD2	Anti-CD16
huCK-1	IL-2	0	0	0	0	0	0	0
	IL-4	2	0	0	0	0	27	3
	IL-5	6	6	6	8	9	28	6
	IL-9	0	0	0	0	0	0	0
	IL-10	0	0	0	0	0	0	0
	IL-13	10	8	7	9	8	33	7
	IL-14	3	2	2	3	4	10	3
	IL-15	2	2	2	3	3	4	2
	IFN- γ	1	1	3	1	3	23	4
huAPO-3	GrmB	374	466	402	397	216	296	324
	GrmA	181	252	371	200	119	275	285
	DAD1	49	63	81	64	32	34	58
	FAST kinase	0	0	0	0	0	0	0
	GrmH	62	82	70	69	39	NA	49
	RVP-1	75	98	116	85	50	245	116
	DR-NM23	0	0	0	0	0	0	0
	Grm3	82	104	84	102	47	53	53
	REQUIEM	0	0	0	0	0	0	0
	CAS	0	0	0	0	0	0	0
	Perforin	239	296	237	232	127	137	192
huAPO-4	Caspase-8	34	34	36	44	43	35	26
	FasL	23	24	37	32	33	51	36
	Fas	23	24	37	32	33	51	36
	FADD	6	8	7	NA	9	13	8
	DR3	9	15	15	13	15	15	13
	FAP	9	12	9	10	12	14	10
	FAF	0	0	0	0	0	0	0
	TRAIL	17	17	18	15	18	27	21
	TNFRp55	23	23	18	21	23	18	16
	TRADD	0	0	0	0	0	0	0
	RIP	6	10	8	9	10	10	7

^a Hybridization signals for the individual mRNA species were normalized against the mean value obtained for the GAPDH/L23 signals ($\times 100$) within each experimental sample. Hence, the detected expression levels for the genes of interest are expressed relative to the expression levels observed for two housekeeping genes. Values in bold print indicate fold changes in gene expression levels ≥ 3 . hu, Human; NA, Not available; TRAIL, TNF-related apoptosis-inducing ligand; FasL, Fas ligand; RIP, receptor-interacting protein; Grm, granzyme; FADD, Fas-associated death domain protein; TRADD, TNFR-associated death domain protein; CAS, caspase; DAD1, defending against death; FAP, FAS-associated phosphatase; FAF, FAS-associated protein factor; RVP-1, rat ventral prostate.




FIGURE 5. Anti-CD2 mAbs, but not alefacept or anti-CD16 mAb, induce cytokine expression in IL-2-expanded human NK cells. The figure depicts a representative RPA experiment using the hCK1 (cytokine) probe set. In vitro IL-2-expanded NK cells were incubated with the mAbs and fusion proteins as indicated for 4 h at 37°C, and the purified RNA was analyzed by RPA. Detection of mRNA species was conducted by acrylamide electrophoresis, followed by autoradiography. Identification of the specific mRNA species was determined as described in *Materials and Methods*.

mAb pair. These data indicate again, as noted for CD25 up-regulation (Fig. 2B), that these NK cells are not refractory to activation via CD2, but fail to provide evidence for alefacept recruitment of CD2-mediated signaling cascades.

Discussion

Taken together the data presented herein suggest that upon coengagement of CD2 and CD16, alefacept induces signals in and stimulates CD16⁺ (e.g., NK) cells to release granzyme B, which, acting in concert with perforin, induces the activation of substrates, potentially caspases, and consequently apoptosis in ligand-expressing (CD2⁺) target cells (NK and potentially sensitive T cells). In the case of alefacept-induced NK cell apoptosis, this may be a fratricidal process similar to that previously reported to be induced by a CD2-specific mAb (46). The patterns of ERK activation and gene induction (the RPA data) observed upon CD2 mAb, CD16 mAb, and alefacept induction suggest that in the NK cells employed in the studies herein, alefacept primarily stimulates the CD16 pathway to generate effector functions. This contrasts with data showing that both the Ag and Fc binding domains of Herceptin and Rituxan engage their molecular receptors (*c-erbB2*, CD20, and FcγR) to induce cellular activation and ADCC (4, 10–12). This distinction may reflect the fact that Abs typically have 100- to 1000-fold higher affinities for their cellular receptors than does LFA-3 for CD2. In the case of alefacept, the data generated using the Fcγ isoforms suggest that binding to CD2 may function primarily to increase alefacept's avidity for FcγR on NK cells and/or macrophages and to target their effector functions to sen-

sitive (apposing) CD2⁺ (T or NK) cells. This is consistent with data showing that CD16⁺ cells are required for alefacept inhibition of T cell proliferation in MLR (14). These findings are further substantiated by studies employing a variant of alefacept, which was found to be less active in CD2/CD16-mediated bridging assays. Administration of this variant was observed to have lower efficacy in a small clinical trial in psoriasis patients and to have lesser effects on the peripheral T cell counts of monkeys and humans (Biogen, unpublished observations). Together these results suggest that alefacept induces the signaling and activation of the CD16⁺ cells and cytolysis of sensitive CD2⁺ cells in vivo, leading to the diminution of peripheral T cell counts in rodents and primates.

As in the case of Ab-dependent (NK/K) cell-mediated cytolysis, our data suggest that the signaling pathways that are activated in alefacept-mediated apoptosis involve the membranolytic agent perforin (47, 48) and the granzyme serine proteases. These are released from secretory vesicles in the killer cell cytoplasm into the target cells (49) where the granzymes access intracellular substrates and initiate a caspase-dependent or independent apoptotic cascade (48, 50). Given the higher levels of surface CD2 expression in preactivated or memory/effector T cells (19) and observations that activated cells are more susceptible to apoptotic pathways (51–53), these cells may be selectively targeted by alefacept, resulting in the selective decrease in the numbers of memory-effector CD2⁺ CD45RO⁺ T cells in the blood of psoriatic patients treated with alefacept in clinical trials (23). It should be considered that such alefacept activation of FcγR⁺ effector cells leading to apoptosis of sensitive CD2⁺ cells may not be restricted to NK cells, as macrophages also express CD16 and are implied in the effect of alefacept in NK cell-depleted human CD2 transgenic mice (14). Additionally, the potential exists for alefacept to mediate effects via other IgG1 binding FcγR, and in this regard alefacept can induce signaling in CD2⁺ Jurkat cells that have been transfected with CD64 (data not shown). However, results to date do not provide direct evidence that CD64 influences the biological activity of alefacept.

Finally, the definition of the molecular players underlying the cellular and biochemical mechanism(s) influencing the efficacy and patient responsiveness to alefacept may contribute to identifying segments of patient populations likely to derive the most gain from alefacept treatment. The results herein suggest that studies investigating polymorphisms in the molecular targets of alefacept (e.g., CD2, FcγR, particularly CD16, and the participants downstream in its signaling cascade) and their expression in patients undergoing alefacept treatment may reveal correlations with therapeutic efficacy, as has recently been shown for Rituximab (54).

Acknowledgments

We thank Irene Sizing, Donna Hess, and Christopher Benjamin of Biogen, Inc., for their assistance with the generation and characterization of the anti-CD2 mAbs used in this study.

References

1. Eccles, S. A. 2001. Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger? *Breast Cancer Res.* 3:86.
2. Waldmann, H. 2001. Therapeutic approaches for transplantation. *Curr. Opin. Immunol.* 13:606.
3. Isaacs, J. D., J. Greenwood, and H. Waldmann. 1998. Therapy with monoclonal Abs. II. The contribution of Fcγ receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. *J. Immunol.* 161:3862.
4. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nat. Med.* 6:443.
5. Peach, R. J., J. Bajorath, W. Brady, G. Leytze, J. Greene, J. Naemura, and P. S. Linsley. 1994. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. *J. Exp. Med.* 180:2049.

6. Ravetch, J. V., and S. Bolland. 2001. IgG Fc receptors. *Annu. Rev. Immunol.* 19:275.
7. Shields, R. L., A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadler, B. Li, et al. 2001. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcγRn and design of IgG1 variants with improved binding to the FcγR. *J. Biol. Chem.* 276:6591.
8. Clark, M. R. 1997. IgG effector mechanisms. *Chem. Immunol.* 65:88.
9. Friend, P. J., G. Hale, L. Chatenoud, P. Rebello, J. Bradley, S. Thiru, J. M. Phillips, and H. Waldmann. 1999. Phase I study of an engineered aglycosylated humanized CD3 Ab in renal transplant rejection. *Transplantation* 68:1632.
10. Pegram, M. D., A. Lipton, D. F. Hayes, B. L. Weber, J. M. Baselga, D. Tripathy, D. Baly, S. A. Baughman, T. Twaddell, J. A. Glaspy, et al. 1998. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal Ab plus cisplatin in patients with HER2/neu-over-expressing metastatic breast cancer refractory to chemotherapy treatment. *J. Clin. Oncol.* 16:2659.
11. Carter, P., L. Presta, C. M. Gorman, J. B. Ridgway, D. Henner, W. L. Wong, A. M. Rowland, C. Kott, M. E. Carver, and H. M. Shepard. 1992. Humanization of an anti-p185HER2 Ab for human cancer therapy. *Proc. Natl. Acad. Sci. USA* 89:4285.
12. Leget, G. A., and M. S. Czuczman. 1998. Use of rituximab, the new FDA-approved Ab. *Curr. Opin. Oncol.* 10:548.
13. Miller, G. T., P. S. Hochman, W. Meier, R. Tizard, S. A. Bixler, M. D. Rosa, and B. P. Wallner. 1993. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. *J. Exp. Med.* 178:211.
14. Majeau, G. R., W. Meier, B. Jimmo, D. Kioussis, and P. S. Hochman. 1994. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: structure/function analysis in vitro and in human CD2 transgenic mice. *J. Immunol.* 152:2753.
15. Springer, T. A., M. L. Dustin, T. K. Kishimoto, and S. D. Marlin. 1987. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. *Annu. Rev. Immunol.* 5:223.
16. Bierer, B. E., B. P. Sleckman, S. E. Ratnoffsky, and S. J. Burakoff. 1989. The biologic roles of CD2, CD4, and CD8 in T-cell activation. *Annu. Rev. Immunol.* 7:579.
17. Sanders, M. E., M. W. Makgoba, S. O. Sharrow, D. Stephany, T. A. Springer, H. A. Young, and S. Shaw. 1988. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. *J. Immunol.* 140:1401.
18. Wallace, D. L., and P. C. Beverley. 1990. Phenotypic changes associated with activation of CD45RA⁺ and CD45RO⁺ T cells. *Immunology* 69:460.
19. Majeau, G. R., A. Whitty, K. Yim, W. Meier, and P. S. Hochman. 1999. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2⁺ T cells is independent of cell activation. *Cell. Adhes. Commun.* 7:267.
20. Pepinsky, R. B., L. L. Chen, W. Meier, and B. P. Wallner. 1991. The increased potency of cross-linked lymphocyte function-associated antigen-3 (LFA-3) multimers is a direct consequence of changes in valency. *J. Biol. Chem.* 266:18244.
21. Kanner, S. B., N. K. Damle, J. Blake, A. Aruffo, and J. A. Ledbetter. 1992. CD2/LFA-3 ligation induces phospholipase-Cγ1 tyrosine phosphorylation and regulates CD3 signaling. *J. Immunol.* 148:2023.
22. Krensky, A. M., F. Sanchez-Madrid, E. Robbins, J. A. Nagy, T. A. Springer, and S. J. Burakoff. 1983. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. *J. Immunol.* 131:611.
23. Ellis, C. N., and G. G. Krueger. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. *N. Engl. J. Med.* 345:248.
24. Bos, J. D., and M. A. De Rie. 1999. The pathogenesis of psoriasis: immunological facts and speculations. *Immunol. Today* 20:40.
25. Robert, C., and T. S. Kupper. 1999. Inflammatory skin diseases, T cells, and immune surveillance. *N. Engl. J. Med.* 341:1817.
26. Vivier, E., N. Rochet, M. Ackerly, J. Petrini, H. Levine, J. Daley, and P. Anderson. 1992. Signaling function of reconstituted CD16ζγ receptor complex isoforms. *Int. Immunol.* 4:1313.
27. Mizushima, S., and S. Nagata. 1990. pEF-BOS, a powerful mammalian expression vector. *Nucleic Acids Res.* 18:5322.
28. Crowe, P. D., T. L. VanArsdale, B. N. Walter, C. F. Ware, C. Hession, B. Ehrenfels, J. L. Browning, W. S. Din, R. G. Goodwin, and C. A. Smith. 1994. A lymphotoxin-β-specific receptor. *Science* 264:707.
29. Spaeny-Dekking, E. H., W. L. Hanna, A. M. Wolbink, P. C. Wever, A. J. Kummer, A. J. Swaak, J. M. Middeldorp, H. G. Huisman, C. J. Froelich, and C. E. Hack. 1998. Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. *J. Immunol.* 160:3610.
30. Kataoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. Yonehara, and K. Nagai. 1996. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. *J. Immunol.* 156:3678.
31. Gergely, J., and G. Sarmay. 1990. The two binding-site models of human IgG binding Fcγ receptors. *FASEB J.* 4:3275.
32. Jefferis, R., J. Lund, and J. D. Pound. 1998. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. *Immunol. Rev.* 163:59.
33. Davis, S. J., and P. A. van der Merwe. 1996. The structure and ligand interactions of CD2: implications for T-cell function. *Immunol. Today* 17:177.
34. Rodella, L., R. Rezzani, G. Zauli, A. R. Mariani, R. Rizzoli, and M. Vitale. 1998. Apoptosis induced by NK cells is modulated by the NK-active cytokines IL-2 and IL-12. *Int. Immunol.* 10:719.
35. Ortaldo, J. R., A. T. Mason, and J. J. O'Shea. 1995. Receptor-induced death in human natural killer cells: involvement of CD16. *J. Exp. Med.* 181:339.
36. Deas, O., C. Dumont, M. MacFarlane, M. Rouleau, C. Hebib, F. Harper, F. Hirsch, B. Charpentier, G. M. Cohen, and A. Senik. 1998. Caspase-independent cell death induced by anti-CD2 or staurosporine in activated human peripheral T lymphocytes. *J. Immunol.* 161:3375.
37. Ida, H., and P. Anderson. 1998. Activation-induced NK cell death triggered by CD2 stimulation. *Eur. J. Immunol.* 28:1292.
38. Umehara, H., J. Y. Huang, T. Kono, F. H. Tabassam, T. Okazaki, E. T. Bloom, and N. Domae. 1997. Involvement of protein tyrosine kinase p72^{src} and phosphatidylinositol 3-kinase in CD2-mediated granular exocytosis in the natural killer cell line, NK3.3. *J. Immunol.* 159:1200.
39. Anegón, I., M. C. Cuturi, G. Trinchieri, and B. Perussia. 1988. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. *J. Exp. Med.* 167:452.
40. Sayers, T. J., A. D. Brooks, J. M. Ward, T. Hoshino, W. E. Bere, G. W. Wiegand, J. M. Kelley, and M. J. Smyth. 2001. The restricted expression of granzyme M in human lymphocytes. *J. Immunol.* 166:765.
41. Kashii, Y., R. Giorda, R. B. Herberman, T. L. Whiteside, and N. L. Vujanovic. 1999. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. *J. Immunol.* 163:5358.
42. Eischen, C. M., J. D. Schilling, D. H. Lynch, P. H. Krammer, and P. J. Leibson. 1996. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. *J. Immunol.* 156:2693.
43. Caron, G., Y. Delneste, J. P. Aubry, G. Magistrelli, N. Herbault, A. Blaëcke, A. Meager, J. Y. Bonnefoy, and P. Jeannin. 1999. Human NK cells constitutively express membrane TNF-α (mTNFα) and present mTNFα-dependent cytotoxic activity. *Eur. J. Immunol.* 29:3588.
44. Darmochwal-Kolarz, D., J. Rolinski, B. Leszczynska-Gorzelak, and J. Oleszczuk. 2000. Fas antigen expression on the decidual lymphocytes of pre-eclamptic patients. *Am. J. Reprod. Immunol.* 43:197.
45. Das, S., C. Varalakshmi, and A. Khar. 2000. Target-cell-induced anergy in natural killer cells: suppression of cytotoxic function. *Cancer Immunol. Immunother.* 49:109.
46. Nizet, Y., A. A. Chentoufi, X. Havaux, I. Kinet, F. Cormont, H. Bazin, and D. Latinne. 1999. Apoptosis of human naive NK cells mediated by a rat IgG2b anti CD2 mAb through a fratricidal ADCC reaction. *Immunol. Lett.* 68:229.
47. Atkinson, E. A., M. Barry, A. J. Darmon, I. Shostak, P. C. Turner, R. W. Moyer, and R. C. Bleackley. 1998. Cytotoxic T lymphocyte-assisted suicide: caspase 3 activation is primarily the result of the direct action of granzyme B. *J. Biol. Chem.* 273:21261.
48. Kagi, D., B. Ledermann, K. Burki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. *Nature* 369:31.
49. Browne, K. A., E. Blink, V. R. Sutton, C. J. Froelich, D. A. Jans, and J. A. Trapani. 1999. Cytotoxic delivery of granzyme B by bacterial toxins: evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin. *Mol. Cell. Biol.* 19:8604.
50. Froelich, C. J., K. Orth, J. Turbop, P. Seth, R. Gottlieb, B. Babor, G. M. Shah, R. C. Bleackley, V. M. Dixit, and W. Hanna. 1996. New paradigm for lymphocyte granule-mediated cytotoxicity: target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. *J. Biol. Chem.* 271:29073.
51. Akbar, A. N., M. Salmon, J. Savill, and G. Janossy. 1993. A possible role for bcl-2 in regulating T-cell memory—a "balancing act" between cell death and survival. *Immunol. Today* 14:526.
52. Kabelitz, D., T. Pohl, and K. Pechhold. 1993. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. *Immunol. Today* 14:338.
53. Osborne, B. A. 1996. Apoptosis and the maintenance of homeostasis in the immune system. *Curr. Opin. Immunol.* 8:245.
54. Carron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colomhat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal Ab and polymorphism in IgG Fc receptor FcγRIIIa gene. *Blood* 99:754.